Company news

Oncolys BioPharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]

August 7, 2026

Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer

June 8, 2026

Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer

June 8, 2026

Non-consolidated Financial Results for the Three Months Ended March 31, 2026

May 8, 2026

Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2025

February 8, 2026

Non-consolidated Financial Results for the Nine Months Ended September 30, 2025

November 7, 2025

Non-consolidated Financial Results for the Six Months Ended June 30, 2025

August 8, 2025

Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2024

February 7, 2025

Non-consolidated Financial Results for the Six Months Ended June 30, 2024

August 9, 2024

Announcement of Investigator-Initiated Phase 2 Clinical Trial Agreement For Immunotherapy refractory Esophagogastric adenocarcinoma

December 19, 2023

Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy

October 16, 2023

Non-consolidated Financial Results for the Three Months Ended March 31, 2023

May 12, 2023

Non-consolidated Financial Results for the Nine Months Ended September 30, 2022

November 4, 2022

Announcement of Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Progressive Supranuclear Pals

August 17, 2022

Non-consolidated Financial Results for the Six Months Ended June 30, 2022

August 5, 2022

Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2021

February 10, 2022

Announcement of Enrollment of First Patient in Phase IIa study for OBP-601 (Censavudine, TPN-101) in patients with ALS and/or FTD

January 21, 2022

First Patient Dosed in NRG Oncology Phase I Clinical Trial for Telomelysin(OBP-301)-Chemoradiation Combination Therapy for Esophageal Cancer Patients

December 7, 2021

Announcement of Enrollment of First Patient in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with PSP

November 18, 2021

Non-consolidated Financial Results for the Nine Months Ended September 30, 2021 [Japanese GAAP]

November 5, 2021

Announcement of FDA Clearance of Two IND Applications to Initiate Phase 2 Clinical Trials of OBP-601 (Censavudine, TPN-101)

August 15, 2021

Oncolys BioPharma to partner with Thermo Fisher Scientific for viral vector development and GMP manufacturing of their proprietary oncolytic virus, OBP-301

August 4, 2021

Decks

The 5 newest of 8 decks. Every deck is listed under its year.